Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH
Peter J. Gilling1, Neil Barber2, Mohamed Bidair3, Paul Anderson4, Mark Sutton5, Tev Aho6, Eugene Kramolowsky7, Andrew Thomas8, Ronald P. Kaufman, Jr.9, Gopal Badlani10, Mark Plante11, Mihir Desai12, Leo Doumanian12, Alexis E. Te13, Claus G Roehrborn14
Canadian Journal of Urology, Vol.29, No.1, pp. 10960-10968, 2022
Abstract Introduction: To determine if Aquablation therapy can maintain long term effectiveness in treating men with moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with a baseline prostate volume between 30 and 80 mL at 5 years compared to TURP.
Materials and methods: In a double-blinded, multicenter prospective randomized controlled trial, 181 patients with moderate to severe LUTS secondary to BPH underwent TURP or Aquablation. The primary efficacy endpoint was reduction in International Prostate Symptom Score (IPSS) at 6 months. The primary safety endpoint was the occurrence of Clavien-Dindo persistent Grade 1… More >